These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6223287)

  • 21. Pharmacokinetics of rosoxacin in human volunteers.
    Park GB; Saneski J; Weng T; Edelson J
    J Pharm Sci; 1982 Apr; 71(4):461-2. PubMed ID: 7086661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prostatic tissue and fluid levels of lomefloxacin (NY-198)].
    Nasu Y; Nishitani Y; Yamada D; Hayata S; Tsugawa M; Kishi M; Mizuno A; Kumon H; Ohmori H; Nanba K
    Hinyokika Kiyo; 1989 Mar; 35(3):551-6. PubMed ID: 2735259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D; O'Hare MD; Robbins MJ; Wall RA; Williams AH; Cremer AW; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occurrence of gram negative bacteria in midstream bladder urine and their sensitivity to quinoline derivatives.
    Esposito S; Galante D; Pennucci C; Barba D
    Microbiologica; 1985 Jul; 8(3):269-76. PubMed ID: 3162081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bactericidal intraprostatic concentrations of norfloxacin.
    Bologna M; Vaggi L; Forchetti CM; Martini E
    Lancet; 1983 Jul; 2(8344):280. PubMed ID: 6135100
    [No Abstract]   [Full Text] [Related]  

  • 26. The pharmacokinetics and tissue penetration of norfloxacin.
    Adhami ZN; Wise R; Weston D; Crump B
    J Antimicrob Chemother; 1984 Jan; 13(1):87-92. PubMed ID: 6230344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The fluoroquinolones for urinary tract infections: a review.
    Cunha BA
    Adv Ther; 1994; 11(6):277-96. PubMed ID: 10150268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of urinary tract infections].
    Borsa F; Humbert G
    Rev Prat; 1985 Mar; 35(15):843-51. PubMed ID: 3159070
    [No Abstract]   [Full Text] [Related]  

  • 29. Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans.
    Barre J; Houin G; Tillement JP
    J Pharm Sci; 1984 Oct; 73(10):1379-82. PubMed ID: 6594505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Susceptibility in vitro to certain quinolines of gram-negative bacteria and gram-positive cocci causing urinary tract infections].
    Mróz E; Jankowski S; Bartelmus J; Grzybek-Hryncewicz K; Ruczkowska J; Starek J; Boratyńska M
    Med Dosw Mikrobiol; 1993; 45(1):115-8. PubMed ID: 8231429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.
    Nakamura S; Kurobe N; Kashimoto S; Ohue T; Takase Y; Shimizu M
    Antimicrob Agents Chemother; 1983 Jul; 24(1):54-60. PubMed ID: 6226241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mictral: nalidixic acid improved?
    Drug Ther Bull; 1981 Aug; 19(18):72. PubMed ID: 7021117
    [No Abstract]   [Full Text] [Related]  

  • 33. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT
    Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections.
    Vogel R; Deaney NB; Round EM; VandenBurg MJ; Currie WJ
    J Antimicrob Chemother; 1984 May; 13 Suppl B():113-20. PubMed ID: 6234271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
    O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(4):253-7. PubMed ID: 2941257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The in-vitro activity of EN 272, a quinolone-7-carboxylic acid, in comparison with other quinolones.
    Neu HC
    J Antimicrob Chemother; 1985 Jul; 16(1):43-8. PubMed ID: 3862659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Norfloxacin sensitivity of bacterial pathogens of urinary tract infections].
    Modde H
    Schweiz Rundsch Med Prax; 1985 Apr; 74(17):439-42. PubMed ID: 3159064
    [No Abstract]   [Full Text] [Related]  

  • 38. In-vitro activity of antifungal agents in combination with four quinolones.
    Petrou MA; Rogers TR
    Drugs Exp Clin Res; 1988; 14(1):9-18. PubMed ID: 3292181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enrofloxacin concentrations in dogs with normal prostate and dogs with chronic bacterial prostatitis.
    Dorfman M; Barsanti J; Budsberg SC
    Am J Vet Res; 1995 Mar; 56(3):386-90. PubMed ID: 7771709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antimicrobial spectrum of norfloxacin.
    Newsom SW
    J Antimicrob Chemother; 1984 May; 13 Suppl B():25-31. PubMed ID: 6234272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.